1. Perspectives in Psoriasis: Assessing Treatment Efficacy—Which Measures, What Do They Tell Us?

4. Psoriasis Area Severity Index (PASI)

5. PASI 50, 75, 90

6. Calculation of PASI

7. Severity of Psoriatic Lesions

9. Dermatology Life Quality Index (DLQI)

12. Scoring DLQI

13. Physician’s Global Assessment (PGA)

15. PASI 75 and 90 Responses Achieved With Biologics (2014): Data From Pivotal Phase 3 Studies

16. Secukinumab Superior to Ustekinumab in Clearing Skin in Moderate-to-Severe Plaque Psoriasis: CLEAR Study 16-Week Results

17. Secukinumab Phase 3: Robust and Sustained Responses to Week 52

18. Ixekizumab for Treatment of Moderate-to-Severe Plaque Psoriasis

20. Improving Magnitude of Response: QoL Is Maximized in Patients Who Achieve PASI 90-100 Response

21. Secukinumab Phase 3: PASI 90 Provides Rapid and Sustained QoL Improvement Compared With PASI 75-89

22. Ixekizumab Phase 3 Trials: PASI 100 and PASI 90 Associated With Significantly Improved DLQI vs PASI 75

24. Improving Long-term Response: Sustained Remission Is a Key Treatment Goal

26. Some Issues With PASI

27. Multiple Dimensions

28. Historical Dimension

29. Temporal Dimension

30. Other Factors to Consider

31. Some Issues With DLQI

32. DLQI Over a Lifetime Is Worse Than at a Given Point in Time

34. What Is CLCI?

35. 5 Key Components to CLCI

36. Coping Strategies Mediate the Effects of Psoriasis

37. Fundamental Requirements of a New Tool

38. Simplified Psoriasis Index (SPI)

39. Learning Points

41. Abbreviations